We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Hospital Acquired Infections Testing Kits Market to Reach USD 1.8 Billion by 2026

By LabMedica International staff writers
Posted on 08 Apr 2022

The global hospital acquired infections testing kits market is expected to grow at a CAGR of 12. More...

7% from USD 1.12 billion in 2021 to USD 1.27 billion in 2022 and is projected to grow further at a CAGR of 8.8% to USD 1.78 billion in 2026, driven by increased incidence of chronic diseases. The rates of hospital acquired infection are higher among patients with increased susceptibility due to old age and underlying chronic diseases, such as COVID-19.

These are the latest findings of The Business Research Company (London, UK), a market intelligence firm.

The unprecedented coronavirus outbreak has caused a surge in the demand for hospital acquired infections testing kits, due to the rise in hospital acquired infections during the pandemic. The pandemic has raised enormous concerns over the quality of care in hospitals, due to the rising number of patients during COVID-19 and the change in staffing numbers. Multiple hospitals have experienced an increase in staffing levels, with traveling nurses reporting that these nurses were unfamiliar with hospital infection control processes. Such circumstances have made it difficult for hospitals to maintain patient safety and quality of care.

Increasing healthcare expenditure is predicted to drive a surge in the demand for hospital acquired infections testing kits. The growth in healthcare expenditure is aiding governments and organizations to spend more on prescription drugs, hospitals, and physical & clinical services, thereby driving the hospital acquired infections testing kits market. Consequently, the rise in healthcare spending will continue to drive an increase in the demand for hospital acquired infections testing kits in the near future.

Geographically, North America held the largest share of 36.2% of the global hospital acquired infections testing kits market in 2021, followed by the Asia-Pacific and other regions. Going forward, South America, Africa and the Middle East will be the world’s fastest-growing markets for hospital acquired infections testing kits with a CAGR of 9.3%, 8.8% and 8.8%, respectively, followed by the Asia Pacific and Western Europe.

Related Links:
The Business Research Company 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.